Empowering precision drug design to transform pharmaceuticals
Liquidia Technologies’ mission is to transform patients’ lives with precise drug particles.
Healthcare organizations of all types and sizes are experiencing unprecedented market pressure to deliver better results at reduced costs. Liquidia is actively tackling those challenges.
Liquidia’s method for precisely engineering drug particles to new specification enhances the therapeutic potential of the molecule for the patient, while minimizing risk and reducing time to market. PRINT® technology gives the pharmaceutical industry the power to produce more stable, clinically-effective products at scale, and reduce manufacturing complexity and cost.
Liquidia’s proprietary PRINT technology brings the pharmaceutical industry the ability to design drug particles uniformly and across nearly any number of compositions, size, or shapes. This novel process optimizes the performance of existing or new therapeutics, whether they are based on small molecules, peptides or biologics. The end result? Medications work as planned, the first time around. Patients get better and feel better faster.
PRINT technology integrates proprietary particle molding technology with a modular, roll-to-roll manufacturing process to create precisely-constructed cavities in which particle chemistry can occur. This approach overcomes the design and loading level limitations of existing particle technologies.
PRINT technology applies best practices from several sectors, including nano-scale techniques from the semiconductor industry and scalable processes from the films industries, to create a novel, highly cost-effective cGMP-compliant process. With PRINT technology, companies no longer need to purchase and manage multiple specialized technologies to achieve commercial-scale production.
This level of control and precision has simply not been broadly available to the pharmaceutical industry before.
PRINT particles can be designed to address specific pharmacological or therapeutic objectives, such as optimizing the route of administration, improving solubility, enhancing stability or extending therapeutic effects, thereby improving efficacy, safety and convenience for the patient.
This simple, elegant solution is applicable to virtually any therapeutic area or molecule, and offers the opportunity to engineer a range of medicines, including drugs and biologics, single agents and combinations, and vaccines.
Drug delivery technologies have been hampered in adapting to specific challenges, including molecules chemistry. By controlling size, composition and/or shape, the PRINT technology can deliver on the potential of drug delivery to improve medicines broadly.
Shifting economics for pharmaceutical companies have elevated the importance of cost and quality management. PRINT technology allows for rapid transition of PRINT-enabled therapies from the laboratory, to clinical development, to scalable commercial production.
PRINT technology changes drug formulation and production through novel and precise engineering techniques, which have been shown to enhance clinical efficacy.
This flexible technology can work across a wide range of therapies, according to third-party reviews.
Pharmaceutical companies can reduce manufacturing costs and complexity, thanks to PRINT’s highly-repeatable and efficient particle fabrication processes.
Liquidia is applying PRINT technology toward internal, licensed, and joint product development opportunities. The pipeline strategy is focused on improving currently approved products in order to minimize development risk and increase speed to market.
By leveraging PRINT technology, Liquidia’s business model is highly capital efficient in the following ways:
- Liquidia is able to improve existing drugs to reach their full therapeutic potential, without having to incur all of the R&D expenses of a truly novel molecule.
- PRINT is an elegant, simple manufacturing process that adds minimal costs while creating significant improvement in the performance of approved medicines.
- Additionally, Liquidia is able to leverage non-dilutive capital from partnerships to invest in the further development of capabilities and internal programs.
Liquidia is advancing both internal product candidates as well as partnered programs that provide additional revenue streams.
Current product candidates entering clinical development span LIQ861 for inhaled medicine and LIQ865 for pain management. Liquidia’s partners including top biopharmaceutical companies such as GlaxoSmithKline, are actively exploring ways to leverage PRINT technology for new therapies.
Liquidia will continue to explore partnership opportunities with companies seeking new approaches for more controllable, efficient drug development.
Liquidia is helping the pharmaceutical industry put the needs of patients first. PRINT technology is flexible, scalable and meets pressing marketplace needs for improved drug delivery. These advantages give Liquidia a bright and expansive future in biopharmaceutical innovation.